Hypervitaminosis B12 in Maintenance Hemodialysis Patients Receiving Massive Supplementation of Vitamin B12

1986 ◽  
Vol 9 (6) ◽  
pp. 417-420 ◽  
Author(s):  
G. Mangiarotti ◽  
C. Canavese ◽  
M. Salomone ◽  
A. Thea ◽  
A. Pacitti ◽  
...  

We have administered routinely a multivitamin preparation containing a megadose of B12 to 106 hemodialysis patients after dialysis treatments. We found that these patients had very high levels of serum vitamin B12 which returned to original values only after a period of three years after stopping the vitamin. Discontinuing therapy had no effect on hemoglobin, mean erythrocyte corpuscular volume, or motor nerve conduction velocity. It is not known whether maintaining a prolonged high level of vitamin B12 is harmful. However, animal and epidemiologic studies have suggested that both cobalamin and cobalt may be potentially toxic. In view of the absence of demonstrable benefit and the possible risk of toxicity, we believe that the use of such megadose vitamin compounds in dialysis patients should be re-evaluated.

1987 ◽  
Vol 12 (2) ◽  
pp. 211-217
Author(s):  
MARIE A. BADALAMENTE ◽  
L. C. HURST ◽  
S. B. PAUL ◽  
A. STRACHER

This investigation describes the use of the calcium-activated protease inhibitor, leupeptin, as an adjunctive therapy to the microsurgical repair of median nerves in a primate model. Our results indicate that leupeptin facilitates morphological recovery in denervated thenar muscles and in distal sensory and mixed motor-sensory nerve trunks and functional recovery measured by motor nerve conduction velocity. Toxicological testing of leupeptin showed that, when administered at a dose of 12mg/kg, intramuscularly, once daily, haematological and clotting profiles were not adversely affected.


Sign in / Sign up

Export Citation Format

Share Document